Based on more than 50,000 assays with samples collected across over 150 sites, ClearNote Health has produced multiple peer-reviewed papers including detection data from several cancer types, including pancreatic and ovarian.
5-hydroxymethylcytosine analysis reveals stable epigenomic changes in tumor tissue that enable cancer detection in cell-free DNA
Analytical Validation of an Early Detection Pancreatic Cancer Test Using 5-Hydroxymethylation Signatures
Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD-1 treatment response and resistance biology in non- small cell lung cancer
Epigenomic Blood-Based Early Detection of Pancreatic Cancer Employing Cell-Free DNA
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
The Cell Type-Specific 5hmC Landscape and Dynamics of Healthy Human Hematopoiesis and TET2-Mutant Preleukemia
A human tissue map of 5-hydroxymethylcytosines exhibits tissue specificity through gene and enhancer modulation
Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA
Pilot study demonstrating changes in DNA hydroxymethylation enable detection of multiple cancers in plasma cell-free DNA
Detection of early stage pancreatic cancer using 5-hydroxymethylcytosine signatures in circulating cell free DNA
5-Hydroxymethylcytosine signatures in cell-free DNA provide information about tumor types and stages
Cell-free DNA 5-hydroxymethylcytosine Profiling for the Assessment of Colorectal Cancer Biology and Treatment Response in Blood.
5hmC-seq of mCRPC cfDNA identifies loss of AR signaling in NEPC and DNPC
A tumor-naïve method for estimating tumor fraction using 5-hydroxymethylation cytosine in cell–free DNA
”Learn more about how our platform is helping accelerate drug development and advancing precision medicine.”
Gulfem Guler, PhD
Vice President, Translational Research, Head of Biopharma Development
ClearNote Health
